Bcl-2/Bcl-xL Inhibitor Solid Forms for Solubility and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current literature lacks research on the polymorphism of Bcl-2/Bcl-xL inhibitor compounds, which can affect their physical and chemical properties such as solubility, stability, and bioavailability, crucial for effective cancer treatment.
Innovation Solution
Development of crystalline and amorphous forms of the Bcl-2/Bcl-xL inhibitor compound, characterized by specific XRPD and MDSC patterns, with methods involving solvent and acid/base mixing followed by slow volatilization or anti-solvent addition to achieve stable forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If the compound is developed without polymorphism research, then the development process is simpler, but the solubility, stability, and bioavailability of the drug are compromised
Solution Approach 1:
The patent applies parameter changes by systematically varying crystallization conditions including solvent types (water, ethanol, acetonitrile, etc.), temperatures (4°C, room temperature, 40°C, 60°C), and pH values to obtain different crystal forms and amorphous forms of the compound, thereby optimizing solubility and bioavailability
Solution Approach 2:
The patent utilizes phase transitions by employing techniques such as slow volatilization of solvents, anti-solvent addition, and temperature-controlled crystallization to transform the compound between different solid phases (crystalline forms I-VIII and amorphous forms), which directly affects the drug's physical and chemical properties
2Reliability
If multiple crystalline and amorphous forms are developed, then the drug stability and solubility are improved, but the manufacturing process becomes more complex
Solution Approach 1:
The patent applies preliminary action by pre-establishing characterization methods (XRPD patterns, MDSC curves, 13C NMR spectra) for each crystal form before production, and pre-optimizing crystallization protocols to ensure consistent quality and reduce manufacturing variability
Solution Approach 2:
The patent systematically controls and documents critical process parameters (solvent composition, temperature, pH, crystallization time) for each form to enable reproducible manufacturing while maintaining the benefits of multiple stable forms
3Reliability
If different crystal forms with varying properties are produced, then the bioavailability is optimized, but the uniformity of drug characteristics becomes harder to control
Solution Approach 1:
The patent applies local quality by selecting specific crystal forms (e.g., Form I for high solubility, Form IV for high stability) for different indications or patient populations, allowing optimization of drug characteristics for specific therapeutic needs while maintaining overall product quality through rigorous characterization
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new forms enhance the stability, solubility, and bioavailability of the inhibitor, providing a basis for improved drug development and formulation.
Implementation Method 1
solid materials cause the spatial arrangement of molecular lattices to be different, forming two or more different crystal structures
Implementation Method 2
characterized in that it has characteristic peaks at the following positions in an X-ray powder diffraction (XRPD) pattern
Implementation Method 3
some solid compounds may also have Amorphous forms. Amorphous refers to the structure of some non-completely crystalline Amorphous regions
Implementation Method 4
Different crystalline forms of the same drug may have significant differences in solubility, melting point, density, stability
Data Source
AI summary
Disclosed herein are a crystalline or amorphous form of a Bcl-2/Bcl-xL inhibitor compound or a salt thereof, and a preparation method and application thereof.